Allergan PLC, which last year agreed to merge with Pfizer Inc., on Thursday said it will buy clinical-stage pharmaceutical company Anterios Inc.
Under the terms of the deal, Allergan will pay Anterios $90 million up front, plus milestone payments.
Anterios is the developer of NDS, a technology that delivers neurotoxins through the skin instead of through injection. Allergan is perhaps best known as the maker of Botox, a neurotoxin with both cosmetic and therapeutic variations used to treat everything from wrinkles to osteoarthritis.
In a news release, Allergan Executive Vice President David Nicholson said the deal allows Allergan to advance “a new delivery system and formulations that are appealing to both patients and physicians.”
Allergan also will get global rights to ANT-1207, a topical drug being investigated for the use of excessive sweating, acne and crow’s feet.
Allergan in November agreed to a more than $150 billion tie-up with Pfizer, a historic merger that would create the world’s biggest drugmaker. The combined company will have top-selling products including Pfizer’s Prevnar pneumonia vaccine and Allergan’s Botox, and an industry-topping R&D budget.
By Chelsey Dulaney
Source: Wall Street Journal
The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.
BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.
Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.
